3 results
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
The primary objective is to select one of two platinum strategies to be used in this regimen for use as experimental arm in Phase III. This is a screening feasibility study addressing purely investigational approaches.
Neuroendocrine carcinomas are distinguished clinically from neuroendocrine tumours by their rapid growth and early development of metastases. Both large and small cell neuroendocrine carcinomas are generally treated based upon chemotherapy regimens…